Brought to you by 
GSK improves position in emerging markets with Egyptian buy
17 Oct 2008
Executive Summary
Bristol-Myers Squibb has sold its mature products business in Egypt to GlaxoSmithKline for $210mm. The acquisition gives GSK a leading position with a 9% share of this emerging pharmaceutical market, which is worth approximately $2.1bn.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Divestiture/Spin-Out
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK improves position in emerging markets with Egyptian buy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice